Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05116475 | Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases(ALADDIN) | recruiting | Phase 3 | 152 | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie |
| 1 |
| Mar 12, 2024 |
| clinicaltrials |
| NCT04642027 | PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy(PERYTON) | recruiting | Phase 3 | 538 | University Medical Center GroningenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05173272 | Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer | recruiting | Phase 3 | 286 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06177015 | Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT05302284 | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | recruiting | Phase 3 | 452 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04242017 | Long-term Better Than Short-term ADT With Salvage RT(LOBSTER) | recruiting | Phase 2 / Phase 3 | 394 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT05781217 | Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624(URONCOR 06-24) | recruiting | Phase 3 | 534 | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología RadioterápicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03216525 | Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol | recruiting | Phase 3 | 136 | Brigham and Women's HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04989647 | Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy(CERVANTES) | recruiting | Phase 3 | 514 | The Central and Eastern European Gynecologic Oncology GroupOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05983783 | Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04654338 | 2 Ablative RadioTherapy Treatments for Prostate Cancer(EARTH) | recruiting | Phase 2 / Phase 3 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT02429687 | TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors(MOGCT-01) | recruiting | Phase 3 | 129 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02429700 | TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors(SCST-01) | recruiting | Phase 3 | 132 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03458221 | Signal TrAnsduction Pathway Activity Analysis in OVarian cancER(STAPOVER) | recruiting | Phase 2 / Phase 3 | 148 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05019846 | SRT Versus SRT+ADT in Prostate Cancer(SPA) | recruiting | Phase 3 | 310 | Marco Lorenzo BonuOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05255471 | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.(MITO 35B) | recruiting | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04520074 | Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | recruiting | Phase 3 | 590 | Fudan UniversityOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05367206 | Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial(N6C) | recruiting | Phase 3 | 280 | Sun Yat-sen UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT04947059 | Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)(GENSA) | recruiting | Phase 3 | 180 | University of ThessalyOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT04974346 | Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer(PAILACC) | recruiting | Phase 3 | 455 | Zhejiang Cancer HospitalOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT03463252 | Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC | recruiting | Phase 2 / Phase 3 | 224 | West China Second University HospitalOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT04733820 | Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery | recruiting | Phase 3 | 340 | Huazhong University of Science and TechnologyOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03288532 | Renal Adjuvant MultiPle Arm Randomised Trial(RAMPART) | recruiting | Phase 3 | 1,750 | University College, LondonOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04063527 | Phase III Trial of Stage I Ovarian Cancer After Surgery | recruiting | Phase 3 | 360 | Japanese Gynecologic Oncology GroupOTHER | 2 | Aug 30, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Apr 2, 2024source: clinicaltrials